Genetic Polymorphisms in CYP2C19 Cause Changes in Plasma Levels and Adverse Reactions to Anlotinib in Chinese Patients With Lung Cancer

Genetic Polymorphisms in CYP2C19 Cause Changes in Plasma Levels and Adverse Reactions to Anlotinib in Chinese Patients With Lung Cancer

Background: Anlotinib is a small molecular multi-targeting tyrosine kinase inhibitor. Growing evidence indicates that treatment efficacy, and toxicity varies considerably between individuals. Therefore, this study aimed to investigate the relationship between cytochrome P450 (CYP450) gene polymorphi...

Full description

Bibliographic Details
Main Authors:	Tingfei Tan, Gongwei Han, Ziwei Cheng, Jiemei Jiang, Li Zhang, Zitong Xia, Xinmeng Wang, Quan Xia
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-06-01
Series:	Frontiers in Pharmacology
Subjects:	anlotinib lung cancer CYP450 gene polymorphisms plasma concentration adverse reactions
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2022.918219/full

Similar Items

Association between CYP3A4/CYP3A5 genetic polymorphisms and treatment outcomes of atorvastatin worldwide: is there enough research on the Egyptian population?
by: Mohammed G. Maslub, et al.
Published: (2023-09-01)

Retrospective Review of Efficacy and Safety of Anlotinib in Advanced Leiomyosarcoma: A Real-World Study
by: Zou H, et al.
Published: (2022-05-01)

Variations in the Frequencies of Polymorphisms in the CYP450s Genes in Eight Major Ethnicities of Iran: A Review of the Human Data
by: Navid Neyshaburinezhad, et al.
Published: (2022-11-01)

Genetic polymorphism of CYP3A4 is associated with poor response to ifosfamide treatment in children with solid embryonic tumors
by: Luz María Torres Espindola, et al.
Published: (2019-07-01)

Research Progress on Mechanism and Management of Adverse Drug Reactions of Anlotinib
by: Li S, et al.
Published: (2023-11-01)

Genetic Determinants in <i>HLA</i> and Cytochrome P450 Genes in the Risk of Aromatic Antiepileptic-Induced Severe Cutaneous Adverse Reactions
by: Ali Fadhel Ahmed, et al.
Published: (2021-05-01)

Frequency of Important CYP450 Enzyme Gene Polymorphisms in the Iranian Population in Comparison with Other Major Populations: A Comprehensive Review of the Human Data
by: Navid Neyshaburinezhad, et al.
Published: (2021-08-01)

Gene polymorphism of cytochrome P450 significantly affects lung cancer susceptibility
by: Meng Li, et al.
Published: (2019-08-01)

Association between anlotinib trough plasma concentration and treatment outcomes in advanced non-small-cell lung cancer
by: Ling Chen, et al.
Published: (2023-03-01)

The Making of a CYP3A Biomarker Panel for Guiding Drug Therapy
by: Danxin Wang, et al.
Published: (2012-10-01)

Efficacy of Combination of Camrelizumab with Anlotinib as Third-line Therapy for Patients with Advanced Non-small Cell Lung Cancer
by: ZHANG Xiaojuan, et al.
Published: (2023-06-01)

Risperidone plasma level, and its correlation with CYP2D6 gene polymorphism, clinical response and side effects in chronic schizophrenia patients
by: Xiaoyi Wang, et al.
Published: (2024-01-01)

Pharmacogenomics of CYP2C9: Functional and Clinical Considerations
by: Ann K. Daly, et al.
Published: (2017-12-01)

ROLE OF THE CYP1A2 GENE POLYMORPHISM ON EARLY AGEING FROM OCCUPATIONAL EXPOSURE
by: Eshkoor Sa., et al.
Published: (2013-12-01)

Impact of Pomegranate Juice on the Pharmacokinetics of CYP3A4- and CYP2C9-Mediated Drugs Metabolism: A Preclinical and Clinical Review
by: Kenza Mansoor, et al.
Published: (2023-02-01)

Anlotinib Downregulates RGC32 Which Provoked by Bevacizumab
by: Zhujun Liu, et al.
Published: (2022-05-01)

Distribution of CYP2D6 and CYP2C19 gene polymorphisms in Han and Uygur populations with breast cancer in Xinjiang, China
by: Abudukeremu Muzhapaer, et al.
Published: (2024-04-01)

Efficacy and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Advanced Epithelial Ovarian Cancer
by: JIN Huimin, et al.
Published: (2022-10-01)

A Robust and Fast/Multiplex Pharmacogenetics Assay to Simultaneously Analyze 17 Clinically Relevant Genetic Polymorphisms in <i>CYP3A4</i>, <i>CYP3A5</i>, <i>CYP1A2</i>, <i>CYP2C9</i>, <i>CYP2C19</i>, <i>CYP2D6</i>, <i>ABCB1,</i> and <i>VKORC1</i> Genes
by: Camille Tron, et al.
Published: (2022-05-01)

Effects of CYP2D6 gene polymorphism on plasma concentration and therapeutic effect of olanzapine
by: Ye Yang, et al.
Published: (2024-04-01)

RETRACTED: The efficacy and adverse effects of anlotinib in the treatment of high-grade glioma: A retrospective analysis
by: Fangcheng Shen, et al.
Published: (2023-02-01)

Isoenzimas do CYP450 e biotransformação de drogas
by: Elisabeth Aparecida Audi, et al.
Published: (2008-05-01)

Detoxification Cytochrome P450s (CYPs) in Families 1–3 Produce Functional Oxylipins from Polyunsaturated Fatty Acids
by: Jazmine A. Eccles, et al.
Published: (2022-12-01)

A Retrospective Study of Anlotinib Combined with Anti-PD-1 Inhibitors in the 2nd or Later-Line Treatment of Advanced Solid Tumors
by: Li SH, et al.
Published: (2023-10-01)

Practice of CYP450 genotyping and phenotyping in children in a real-life setting
by: Frédérique Rodieux, et al.
Published: (2023-02-01)

Investigation of cytochrome p450 CYP1A2, CYP2D6, CYP2E1 and CYP3A4 gene expressions and polymorphisms in alcohol withdrawal (eng)
by: Nazife Taşçıoğlu, et al.
Published: (2021-09-01)

Influence of CYP450 Enzymes and ABCB1 Polymorphisms on Clopidogrel Response in Moroccan Patients with Acute Coronary Syndromes
by: Mouhrach I, et al.
Published: (2023-10-01)

Anlotinib Exerts Inhibitory Effects against Cisplatin-Resistant Ovarian Cancer In Vitro and In Vivo
by: Yurou Ji, et al.
Published: (2022-12-01)

Altered CYP19A1 and CYP3A4 Activities Due to Mutations A115V, T142A, Q153R and P284L in the Human P450 Oxidoreductase
by: Sameer S. Udhane, et al.
Published: (2017-08-01)

Cases of Adverse Reaction to Psychotropic Drugs and Possible Association with Pharmacogenetics
by: Irina Piatkov, et al.
Published: (2012-10-01)

Efficacy and safety of antipsychotics in adolescents with an acute psychotic episode in relation to the activity of CYP3A and CYP2D6 isoenzymes
by: D. V. Ivashchenko, et al.
Published: (2020-12-01)

In vitro and In silico studies of interactions of cathinone with human recombinant cytochrome P450 CYP(1A2), CYP2A6, CYP2B6, CYP2C8, CYP2C19, CYP2E1, CYP2J2, and CYP3A5
by: Sharoen Yu Ming Lim, et al.
Published: (2022-01-01)

Effects of CYP2C19 variants on the metabolism of tapentadol in vitro
by: Ren-ai Xu, et al.
Published: (2022-05-01)

Associations of genetic polymorphisms of the vitamin D pathway with blood pressure in a Han Chinese population
by: Xiaoman Ye, et al.
Published: (2019-07-01)

Association of CYP1A1*2C Variant (Ile464Val Polymorphism) and Some Hematological Parameters with Acute Myeloid Leukemia (AML) and Chronic Myeloid Leukemia (CML) in Erbil-Iraq.
by: Sumaya Basit Abdullah ,Mustafa Saber Al-Attar
Published: (2023-06-01)

Central retinal vein occlusion with cerebral infarction secondary to anlotinib treatment: a case report and literature review
by: Yingying Chen, et al.
Published: (2023-06-01)

Genetic polymorphism of CYP2D6 gene among Egyptian hypertensive cases
by: Ahmed A.A. Ali, et al.
Published: (2013-08-01)

The Impact of the CYP2D6 and CYP1A2 Gene Polymorphisms on Response to Duloxetine in Patients with Major Depression
by: Julian Maciaszek, et al.
Published: (2023-08-01)

The 1β-Hydroxy-Deoxycholic Acid to Deoxycholic Acid Urinary Metabolic Ratio: Toward a Phenotyping of CYP3A Using an Endogenous Marker?
by: Gaëlle Magliocco, et al.
Published: (2021-02-01)

Effects of CYP3A4*22 polymorphism on trough concentration of tacrolimus in kidney transplantation: a systematic review and meta-analysis
by: Jung Sun Kim, et al.
Published: (2023-07-01)